Quadrant Capital Group’s CareDx CDNA Stock Holding History

Quadrant Capital Group’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-293	Closed	-$5.09K	–	1476
2026 Q1	$5.09K	Hold	293	–	–	﹤0.01%	2349
2025 Q4	$5.52K	Hold	293	–	–	﹤0.01%	2347
2025 Q3	$4.26K	Buy	+293	New	+$4.18K	﹤0.01%	2347
2025 Q2	–	Sell	-293	Closed	-$5.2K	–	1569
2025 Q1	$5.2K	Hold	293	–	–	﹤0.01%	2347
2024 Q4	$6.27K	Hold	293	–	–	﹤0.01%	2258
2024 Q3	$9.15K	Hold	293	–	–	﹤0.01%	2170
2024 Q2	$4.55K	Hold	293	–	–	﹤0.01%	2317
2024 Q1	$3.1K	Hold	293	–	–	﹤0.01%	2418
2023 Q4	$3.52K	Buy	+293	New	+$2.4K	﹤0.01%	2362
2023 Q3	–	Sell	-47	Closed	-$400	–	2696
2023 Q2	$400	Sell	47 -22	-32%	-$183	﹤0.01%	2595
2023 Q1	$631	Buy	69 +59	+590%	+$755	﹤0.01%	2577
2022 Q4	$114	Sell	10 -88	-90%	-$1.3K	﹤0.01%	2716
2022 Q3	$2K	Buy	+98	New	+$2.1K	﹤0.01%	2349
2022 Q1	–	Sell	-16	Closed	-$1K	–	2512
2021 Q4	$1K	Buy	+16	New	+$835	﹤0.01%	2263
2021 Q3	–	Sell	-1	Closed	–	–	2518
2021 Q2	$0	Buy	+1	New	+$79	﹤0.01%	2423

Other funds holding CDNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $38.8B AUM 41.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrant Capital Group's CDNA Position: Q2 2026 in Review

Quadrant Capital Group sold out of CareDx (CDNA) in Q2 2026, closing a stake of 293 shares — an estimated $5.09K sold.

Quadrant Capital Group first reported a position in CDNA in Q2 2021 and held it in 15 quarters. The position peaked at $9.15K in Q3 2024. 227 funds tracked by Wall St. Rank hold CDNA as of Q2 2026.

Quadrant Capital Group reported no remaining CareDx position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 293 CareDx shares in Q2 2026, an estimated $5.09K.
Quadrant Capital Group first reported a position in CareDx in Q2 2021 and held it in 15 quarters.
Quadrant Capital Group's CareDx position peaked at $9.15K in Q3 2024.
227 funds tracked by Wall St. Rank held CareDx as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.